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Summary 
Background  
Food allergy is an increasingly common health problem in Western populations. Epidemiological 
studies have suggested both positive and negative associations between food allergy and infection 
with the gastric bacterium Helicobacter pylori.  
Objective  
The objective of this work was to investigate whether experimental infection with H. pylori, or 
prophylactic treatment with H. pylori-derived immunomodulatory molecules, affects the onset and 
severity of food allergy, either positively or negatively. 
Methods 
We infected neonatal C57BL/6 or C3H mice with H. pylori or treated animals with H. pylori 
components (bacterial lysate or the immunomodulator VacA) and subsequently subjected them to 
four different protocols for food allergy induction, using either ovalbumin or peanut extract as 
allergens for sensitization and challenge. Readouts included anaphylaxis scoring, quantification of 
allergen-specific serum IgE and IgG1 and of the mast cell protease MCPT1, as well as splenic T-
helper-2 cell-derived cytokine production. Mesenteric lymph node CD4+FoxP3+ regulatory T-cells 
were subjected to flow cytometric quantification and sorting followed by qRT-PCR, and to DNA 
methylation analyses of the Treg-specific demethylated region (TSDR) within the FOXP3 locus.  
Results  
Mice that had been infected with H. pylori or treated with H. pylori-derived immunomodulators 
showed reduced anaphylaxis upon allergen sensitization and challenge, irrespective of the allergen 
used. Most of the immunologic assays confirmed a protective effect of H. pylori. CD4+FoxP3+ T-cells 
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were more abundant in protected mice and exhibited a stable Treg phenotype characterized by 
FOXP3 TSDR demethylation.  
Conclusions and Clinical Relevance  
H. pylori confers protection against the anaphylaxis associated with ovalbumin and peanut allergy 
and affects the epigenome of T-cells, thereby promoting stable Treg differentiation and 
functionality. Prophylactic treatment with H. pylori-derived immunomodulators appears to be a 
promising strategy for food allergy prevention. 
 
Key words: anaphylaxis, bacterial immunomodulators, epigenetics, food allergy 
 
Introduction 
Food allergy is an increasingly common condition in Western countries as well as Asia, affecting ~6-8 
% of children and ~4 % of adults [1, 2]. It is caused by inappropriate T-cell-driven immune responses 
to harmless food components of milk, eggs, peanuts, tree nuts, seafood, shellfish, soy, wheat (the 
“big eight”) and other foods. Food allergy often co-occurs with other atopic diseases such as allergic 
rhinitis and conjunctivitis, eczema and allergic asthma and is believed to result mechanistically from 
the breakdown of the T-cell suppressive mechanisms conferred by oral immune tolerance. 
Symptoms of food allergy usually occur with a fast onset (from seconds to one hour) and include 
rashes, hives, swelling and itching of parts or the whole face, wheezing, diarrhea, nausea and, in 
severe cases, anaphylaxis. The mainstay of treatment is the strict avoidance of food allergens; 
accidental intake requires epinephrine injections in severe and anti-histamines and steroids in mild 
cases. The benefits of allergen immunotherapy for food allergies are currently unclear and the 
procedures are thus not (yet) recommended.   
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The hygiene [3] and disappearing microbiota [4] hypotheses postulate that the reduced exposure to 
environmental and pathogenic microbes early in life and/or the loss of ancestral indigenous 
microbes colonizing various niches of the human body contribute to an increased allergy risk. Both 
hypotheses have served to explain the dramatic increase of the prevalence of food allergy in 
Western countries. The paradigmatic example of a microbe that is increasingly lost from human 
populations is H. pylori. Chronic infection with this gastric colonizer on the one hand represents an 
important risk factor for the development of gastritis, ulcers and gastric cancer [5, 6] but on the 
other hand appears to confer protection against esophageal disorders such as gastro-esophageal 
reflux disease and esophageal cancer, as well as asthma, allergy and inflammatory bowel diseases [7, 
8]. Whereas the inverse association of H. pylori with allergic asthma, rhinitis and eczema is well 
supported by large epidemiological studies and meta-analyses [9-12], the effects of H. pylori 
positivity on the risk of developing food allergy are controversial. Few reports are available and the 
existing studies suffer from small sample sizes, heterogeneous populations and non-standardized 
methodologies [13]. Several studies have found a positive association of H. pylori, especially of 
strains harboring the virulence factor CagA, with food allergy in children [14, 15] or adults [16]. 
Other studies have found no association [17], or a negative association [12]. The latter study 
reported both a decreased sero-prevalence of H. pylori in food allergy patients relative to controls 
(33% vs. 40% as determined by urea breath test and serology) as well as a reduced production of 
allergic mediators (such as eosinophilic cationic protein and mast cell tryptase) in H. pylori-positive 
relative to H. pylori-negative food allergy patients [12]. Mechanistically, positive associations with 
food allergy were explained by a breakdown of the epithelial barrier to food allergens due to the 
chronic inflammation of the H. pylori-infected gastric mucosa, whereas negative associations were 
attributed to the immunomodulatory activity of H. pylori on the activation and polarization of T-cell 
responses.  
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We have previously examined the role of H. pylori in various experimental models of allergic asthma 
and have consistently detected a strong protective effect, especially of neonatal exposure to the 
bacteria, on the development of allergic asthma in response to various allergens [18-20]. Given the 
controversial results from observational studies in humans with food allergy, the strongly increasing 
prevalence of food allergy in children and adults, and the robust effects observed in our allergic 
asthma models, we asked whether experimental H. pylori infection would alleviate the clinical and 
immunological symptoms of food allergy induced by two different common food allergens. We used 
recombinant ovalbumin and peanut extract, administered via various routes, to trigger anaphylaxis 
symptoms in two strains of mice. When administered intraperitoneally for the purpose of allergen 
challenge, peanut extract was superior to ovalbumin in inducing swelling and edema of the mucosal 
surfaces of the face, as well as a variety of systemic parameters related to Th2, B- and mast cell 
activity. H. pylori infection and H. pylori extract treatment, and also the administration of several 
doses of purified VacA, reduced clinical symptoms of food allergy in all or some of the four examined 
models and decreased Th2 cytokine production, mast cell protease secretion, and allergen-specific 
serum IgG1 levels. The same treatments could be shown to promote Treg numbers, regulatory 
activity and stability by demethylating the TSDR of the FOXP3 locus in regulatory T-cells (Tregs) of 
mesenteric lymph nodes. Our results thus suggest that H. pylori down-modulates immune responses 
to common food allergens by affecting the epigenome of Tregs and promoting their stable lineage 
differentiation, thereby conferring protection against various clinical and immunological hallmarks of 
food allergy.         
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Methods 
Animal experimentation 
C57BL/6 and C3H mice were purchased from Janvier and included in allergy experiments at 5-7 
weeks of age. For the induction of ovalbumin (OVA)-induced food allergy, C57BL/6 mice were 
sensitized twice i.p. with 50 μg OVA (Sigma A5503-5G) emulsified in aluminum hydroxide (Alum 
Imject, Thermo Scientific 77161) on day 0 and 14, followed by challenge via oral gavage on days 28, 
29, 30 and 31 with 60  mg OVA. Symptoms were scored after each of the first three challenges; mice 
were sacrificed by CO2 inhalation 30-45 min after the last challenge and blood and tissue samples 
were collected. For the induction of peanut extract (PE)-induced food allergy, C57BL/6 mice were 
sensitized orally once a week for four weeks with 2 mg PE adjuvanted with 20 μg cholera toxin (List 
Biologicals 101B) followed by either four oral challenges on four consecutive days with 10 mg PE (in 
this model, symptoms were scored after the first three challenges) or two i.p. challenges (with a 
two-day break) with 1 mg PE (in that case, symptoms were scored after the first challenge).  Scoring 
was done for 40 min beginning right after challenge, with scores indicating the following: 0, no sign 
of reaction; 1, repetitive scratching and rubbing around the nose/mouth and head, ear canal digging 
with hind legs; 2, decreased activity with an increased respiratory rate, pilar erecti and/or puffing 
around the eyes and/or mouth; 3, labored respiration and cyanosis around the mouth and tail 
and/or periods of motionless for more than 1 min; lying prone on stomach; 4, slight or no activity 
after prodding/whisker stimuli or tremors and convulsion; 5, death. In the oral challenge models, 
cumulative scores were calculated by adding up three individual scores per mouse. C3H mice were 
sensitized orally once a week for five weeks with 2 mg PE adjuvanted with 20 μg cholera toxin 
followed by two oral challenges on two consecutive days with 14 mg PE (symptoms were scored 
after the first challenge). The processing and analysis of animal tissues is described below; MCPT1 in 
serum was quantified by ELISA (88-7503-88, eBioscience) according to the manufacturer’s 
instructions. All animal experimentation was reviewed and approved by the Zurich Cantonal 
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Veterinary Office (license 170/2014 to A.M.). The H. pylori strain PMSS1 was cultured as previously 
described [21]; mice were infected by oral gavage on day 6 and 7 after birth with 107 to 108 bacteria. 
For the production of H. pylori extract, bacterial cultures were pelleted, washed with PBS, and 
subjected to three freeze-thaw cycles and homogenization using a pressure cell homogenizer 
(Stansted SPCH-18). The homogenate was centrifuged at 3000x g, the resulting supernatant was 
sterile filtered, and the protein concentration was determined by BCA Protein Assay Kit (Thermo 
Scientific 23227). Oligomeric s1m1 type VacA was purified from H. pylori strain 60190 as described 
previously [22]. The dosage of extract and VacA was adjusted to the age of the mice and the 
application mode: extract i.p. 5-100 μg, extract p.o. 50-200 μg, VacA i.p. 5-20 μg. Mice were treated 
with VacA or extract once a week. For the production of peanut extract, partially defatted peanut 
flour (Golden Peanut Company) was extracted overnight in 10x PBS, solid parts were removed by 
centrifugation, and extract was concentrated using Amicon Ultracel 3K centrifugal filters (Merck 
Millipore UFC900324). The final protein concentration was determined by BCA Protein Assay Kit 
(Thermo Scientific 23227). 
 
Allergen-specific ELISAs 
For OVA-specific IgG1 ELISA, high affinity plates were coated with 10 μg OVA in carbonate-
bicarbonate coating buffer (pH 9.6) overnight at 4° C. After washing and blocking with 2 % BSA in 
PBS, serum samples were diluted in 1 % BSA/PBS and added for 2 hours at 37°C. After further 
washing, the plates were incubated for 1 h at 37°C with HRP-coupled anti-mouse IgG1 (eBioscience 
18-4015-82). Wells were washed again before adding HRP substrate and measuring absorbance in a 
Spectromax plate reader. OVA-specific IgE was measured using the same procedure as described for 
IgG1, except that HRP-coupled anti-mouse IgE (GeneTex GTX77227) was used for detection. For PE-
specific IgE ELISA, high affinity plates were coated with 500 μg PE overnight as described above. 
After washing and blocking with 5 % gelatine in PBS at 37°C for 1 hour, serum samples diluted in 2 % 
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BSA/PBS were added to the plate for 2 hours at 37°C. After further washing, the plates were 
incubated with anti-mouse IgE-biotin (BD Biosciences 553419) and washed before avidin-HRP 
(Thermo Scientific 21130) was added. Wells were washed again before addition of HRP substrate 
and absorbance detection in a plate reader.  
 
Re-stimulation of splenocytes and cytokine ELISAs 
Spleens were pushed through a 40 μm cell strainer and washed with PBS prior to red blood cell lysis. 
Splenocytes were seeded into 96 well plates in RPMI 1640 medium (Gibco 21875-034 plus FCS and 
Penicillin-Streptomycin) supplemented with 200 μg/ml PE or OVA. After 4 days in culture, 
supernatants were collected and stored at -20°C until cytokines were quantified by IL-5 (88-7054-88) 
and IL-13 (88-7137-88) ELISA according to the manufacturer’s instructions (eBioscience).  
 
TSDR methylation analysis 
Total mesenteric lymph node cells of male C57BL/6 mice were isolated by means of collagenase type 
IV (Sigma C5138) digestion and pushing through a cell strainer. After fixation, permeabilization and 
washing, the cells were stained with anti-mouse CD4-FITC (Biolegend 100510) and Foxp3-APC 
antibodies (eBioscience 17-5773-82). CD4+Foxp3+ and CD4+Foxp3- cells were sorted on a FACS Aria. 
Genomic DNA was isolated from sorted cell subsets using the NucleoSpin® Tissue kit (Macherey-
Nagel). An additional step was added to the manufacturer’s protocol to remove formaldehyde-
induced crosslinking. Briefly, Chelex-100 beads (Biorad) were added after the lysis step and 
incubated at 95°C for 15 min in a shaker. Chelex-100 beads were spun down and the supernatant 
was transferred to a fresh tube. After addition of an adjusted amount of 100 % ethanol the following 
purification steps were performed according to the manufacturer’s protocol. Genomic DNA was 
converted with bisulfite using the EZ DNA Methylation Kit (Zymo Research) according to the 
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manufacturer’s instructions. The Treg-specific demethylated region (TSDR) was amplified by PCR and 
analyzed by pyrosequencing on a PSQ96MA (Qiagen) as described recently [23]. Primers for 
sequencing were (in 5’ to 3’ direction), S1: CCATACAAAACCCAAATTC, S2: 
ACCCAAATAAAATAATATAAATACT, S3: ATCTACCCCACAAATTT, S4: AACCAAATTTTTCTACCATT), which 
cover CpG motifs 3-12 of the TSDR core region. 
 
Flow cytometric analysis and cell sorting for qRT-PCR 
Total mesenteric lymph node cells of male C57BL/6 mice were isolated by pushing through a cell 
strainer. After fixation, permeabilization and washing, the cells were stained with anti-mouse CD4 
PerCP/Cy5.5 (Biolegend 116012), anti-mouse CD45 BV650 (Biolegend 103151), anti-mouse TCR β 
chain PE/Cy7 (Biolegend 109222), anti-mouse CD8α BV510 (Biolegend 100752), anti-mouse Foxp3 
BV421 (Biolegend 126419), the fixable viability dye eFluor780 (eBioscience 65-0865-14) and flow 
cytometrically measured using a LSR II Fortessa instrument followed by a detailed analysis using 
FlowJo software. For FACS-sorting of regulatory T-cells, mesenteric lymph node cells were stained 
with anti-mouse CD45 BV650 (Biolegend 103151), anti-mouse TCR β chain PE/Cy7 (Biolegend 
109222), anti-mouse CD4 BV711 (Biolegend 100550), anti-mouse CD25 PE (Biolegend 101903), 
fixable viability dye eFluor780 (eBioscience 65-0865-14) and sorted on a FACS Aria. RNA of sorted 
cells was isolated using the RNeasy Mini Kit (Qiagen 74106), converted into cDNA, and subjected to 
TaqMan Real-Time PCR assay using the primers Mm03024075 (Hprt), Mm00475162 (Foxp3), 
Mm01178820 (Tgfb1) and Mm01288386 (IL10; all from Thermo Fisher Scientific). Samples were run 
on a Light Cycler 480 and normalized to the house-keeping gene Hprt.  
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Statistical analysis 
GraphPad Prism 6 was used for all statistical analyses. In all graphs each symbol represents an 
individual animal and horizontal lines indicate medians. The Kruskal-Wallis test followed by Dunn's 
multiple comparisons test was used throughout. Stars are used to indicate the level of significance 
according to the p‐value: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
Results 
Live H. pylori infection or treatment with H. pylori whole cell extract alleviates symptoms in an 
ovalbumin-induced food allergy model 
To assess whether infection with H. pylori or treatment with whole cell extract protects against 
allergic responses to ingested ovalbumin, we either infected neonatal C57BL/6 mice with live H. 
pylori on days 6 and 7 after birth or intragastrically administered weekly doses of whole cell extract 
from day 7 onwards. As adults, mice were subjected to intraperitoneal ovalbumin (OVA, adjuvanted 
with alum) sensitization followed by intragastric OVA challenges (see schematic in Figure 1A). Mice 
were scored for anaphylactic symptoms such as scratching around the nose, mouth and ears, 
decreased activity and increased respiratory rate and puffy eyes for 40 min after each challenge. At 
the study endpoint, serum levels of OVA-specific IgE and IgG1 antibodies, serum levels  of mast cell 
protease 1 (MCPT1), and the splenic production of the Th2 cytokines IL-5 and IL-13 were quantified 
by ELISA. Mice that had been sensitized and challenged with OVA (positive controls) developed mild 
to moderate anaphylactic symptoms accompanied by high serum titers of OVA-specific IgE and IgG1 
and elevated levels of MCPT1, a systemic marker of mast cell degranulation (Figure 1B-D, suppl. 
Figure 1A,B). The re-stimulation of splenic single cell preparations with OVA revealed a clearly 
elevated production of IL-5 and IL-13 relative to control groups that had not been sensitized (but 
challenged) or had never been exposed to OVA (Figure 1E,F). In contrast, mice that were infected 
with H. pylori or had received H. pylori whole cell extract were assigned significantly lower 
anaphylaxis scores, exhibited reduced serum levels of OVA-specific IgG1, and produced lower 
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amounts of splenic Th2 cytokines upon re-stimulation (Figure 1B-F); the assessment of serum MCPT-
1 levels confirmed these trends for the extract treatment, but not for the live infection, and serum 
IgE levels were not reduced by either extract treatment or live infection (suppl. Figure 1A,B). Overall, 
the results indicate that H. pylori infection and extract treatment efficiently reduce anaphylaxis 
symptoms and most other hallmarks of ovalbumin-specific allergy; the effects on anaphylaxis scores 
in particular, the most relevant readout from a clinical perspective, are strong and robust.  
Food allergy symptoms induced by peanut extract are reduced by H. pylori infection and 
treatment with H. pylori extract or the H. pylori immunomodulator VacA 
We next sought to determine if these results could be corroborated in additional models of food 
allergy. As proteins contained in peanuts are among the most common food allergens in Western 
societies, we opted for peanut-specific sensitization and challenge. Mice received four intragastric 
weekly doses of cholera toxin-adjuvanted peanut extract (PE) for the purpose of sensitization, 
followed by intragastric challenge with PE on four consecutive days beginning one week after the 
last sensitization (Figure 2A). Neonatally infected mice and mice treated with either H. pylori extract 
or the purified H. pylori immunomodulator VacA were sensitized and challenged alongside a group 
of positive controls that received no intervention whatsoever. The food allergy symptoms elicited by 
intragastric sensitization and challenge with peanut extract were relatively mild and comparable to 
symptoms induced with OVA (Figure 2B-D). Similar to the OVA model, regular treatment with extract 
or the purified immunomodulator VacA effectively reduced the anaphylaxis scores, but failed to 
affect peanut-specific serum IgE levels; live infection had no significant effect on any of the 
parameters but showed a trend towards lower anaphylaxis scores (Figure 2B,C). MCPT serum levels 
were modestly reduced by all three interventions (Figure 2D), albeit not significantly. In summary, 
we observe in two complementary food allergy models that H. pylori-based prophylactic 
interventions reduce clinically relevant symptoms of food allergy and modulate immunologic 
correlates of the disease.  
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Severe anaphylaxis induced by peanut extract is alleviated by H. pylori  
Both above described models of food allergy produce relatively mild symptoms. Mice rarely develop 
systemic symptoms such as decreased activity or effects on respiration rates. To mimic more severe 
anaphylactic reactions, which can be life-threatening in peanut-allergic children, we devised a model 
that produced significantly higher anaphylaxis scores, accompanied by higher serum MCPT levels 
and stronger cytokine production by restimulated splenocytes relative to the other two models. In 
this model, mice were sensitized orally by four CT-adjuvanted doses of peanut extract followed by 
two intraperitoneal challenges with the same extract (Figure 3A). Most mice of the positive control 
group were assigned anaphylaxis scores of three (defined as labored respiration and cyanosis around 
the mouth and tail and/or periods of motionless for more than 1 min, lying prone on stomach) or 
four (slight or no activity after prodding/whisker stimuli or tremors and convulsion; Figure 3B,C) 
already after the first challenge dose. Anaphylaxis scores were strongly reduced by treatment with 
VacA, but not so much by the other examined interventions (Figure 3B); moreover, the Th2 cytokine 
production of re-stimulated splenocytes (Figure 3D,E) and MCPT and IgE levels measured in serum 
showed only modest trends (suppl. Figure 2A,B). Finally, we switched to a fourth model of food 
allergy, this time using particularly anaphylaxis-sensitive C3H mice [24]. These mice exhibited 
anaphylaxis scores of up to three upon oral sensitization and challenge, and thus indeed proved to 
be more susceptible to peanut extract than C57BL/6 mice also in our hands (suppl. Figure 3A-C). 
Regular H. pylori extract treatment had modest, but not statistically significant, effects on 
anaphylaxis scores, serum MCPT levels and spleen weights (suppl. Figure 3B-E). Treatment with VacA 
had similar effects, but too few mice were analyzed to draw definitive conclusions (suppl. Figure 3B-
E). In summary, the severe anaphylaxis induced by the intraperitoneal administration of allergen to 
sensitized C57BL/6 mice, or the oral challenge of C3H mice, can be reduced somewhat by prior 
infection with H. pylori, or the regular exposure to H. pylori extract or VacA. 
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H. pylori infection, as well as extract and VacA treatment induce demethylation of the Treg-
specific demethylated region (TSDR) in FoxP3+ Tregs, promoting their lineage commitment and 
suppressive activity 
Tregs have been implicated in asthma protection in H. pylori-infected mice and are numerically and 
functionally different in naïve and infected animals [18-20]. To assess whether the interventions 
shown here to confer food allergy protection affect the differentiation and stability of Tregs, we set 
out to quantify the methylation status of CpG motifs (Figure 4A) localized within a region of the 
FOXP3 locus termed TSDR because of its selective demethylation in lineage-committed (stable) Tregs 
[25, 26]. Tregs from pooled mesenteric lymph nodes of 6-8 male mice per group were FACS-sorted 
based on their CD4 and FoxP3 expression, and subjected to genomic DNA extraction, bisulfite 
conversion and TSDR-specific pyrosequencing. CD4+ FoxP3- T-cells were sorted and analyzed in 
parallel. FoxP3- T-cells exhibited a more or less complete methylation of the TSDR, with on average 
96 % methylated CpG motifs (Figure 4B and data not shown); their methylation did not change upon 
intervention (data not shown). In contrast, FoxP3+ T-cells exhibited strong differences in their 
methylation status: whereas FoxP3+ T-cells that had been harvested from naive mice showed 
methylation levels varying between 25-50 % depending on the experiment, this level decreased to 
10 % upon extract treatment, 10-17 % upon live infection and down to 1 % upon VacA treatment 
(Figure 4B). As reported previously [25, 26], the CpG motifs within the TSDR showed very consistent 
methylation patterns within one sample, indicating an all-or-nothing mechanism of demethylation 
that encompasses the entire locus (not all regions could be analyzed in all samples though, 
Figure 4B). Furthermore, flow cytometric analysis of MLN T-cells revealed somewhat higher 
frequencies of FoxP3+ cells among all CD4+ T-cells in VacA-treated and neonatally infected mice, 
whereas overall CD4+ and CD8+ frequencies were similar (Figure 4C). CD4+CD25+ Tregs sorted from 
the MLNs of the same mice receiving interventions expressed modestly more FoxP3 and IL-10 and/or 
TGF- than Tregs from untreated controls, confirming that TSDR demethylation has functional 
consequences with respect to Treg expansion and regulatory  cytokine expression. We conclude 
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from these data that epigenetic marks leading to stable expression of FoxP3, and to the definitive 
lineage commitment of Tregs, reflect the suppressive effects of H. pylori-specific treatments on food 
allergy in the models described above. 
 
Discussion 
Although food allergy represents an important human disorder of increasing prevalence in most 
parts of the world and H. pylori is known to be protective against allergies with respiratory tract 
manifestations [10, 18-20, 27, 28], little experimental or epidemiological evidence is available that 
addresses a possible inverse correlation, or protective effect, of H. pylori in food allergy. One of the 
reasons for this lack of data probably lies in the fact that no universally accepted food allergy model 
exists that would faithfully reflect all or most aspects of the human condition. We have adapted and 
optimized four complementary food allergy models, using various routes of sensitization and 
challenge, two different common food allergens and two mouse strains, to investigate in a 
comprehensive manner whether the presence of H. pylori affects clinically relevant food allergy 
symptoms, in either a beneficial or detrimental way. We found no strong evidence for a promoting 
role of H. pylori in food allergy, as had been suggested in two observational studies in humans [14, 
15]. In contrast, live H. pylori infection or extract or VacA treatment conferred detectable protection 
against anaphylactic symptoms in several of the models; the effects on clinical symptoms were 
associated with protective effects on systemic parameters of food allergy, such as mast cell protease 
levels in serum and allergen-specific IgG1 levels in some but not all models. The effects of H. pylori 
on food allergy were not as impressive as its beneficial effects in models of allergic asthma in which 
neonatal exposure to the bacteria essentially reduces parameters of airway inflammation, airway 
hyper-responsiveness and goblet cell metaplasia to almost background levels [18-20]. The stronger 
effects in the asthma models may have to do with the so-called “gut-lung axis”, the idea of a special 
connection between the mucosal immune systems of the two organs that has been put forward to 
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explain the effects of (deliberate or pathogenic alterations of) the gut microbiota on lung diseases 
[29].  We were able to link the protection against the airway hyper-reactivity, inflammation, 
eosinophilia and excessive mucus production that are hallmarks of allergic asthma to the strong 
suppressive activity of H. pylori-induced Tregs [19, 20]. Here, we present a possible epigenetic 
correlate of the suppressive/protective activity of Tregs in allergy, as these cells- coming from an H. 
pylori-infected host- exhibit an epigenetic signature at their FOXP3 locus that is consistent with 
stable expression of FoxP3 and stable lineage differentiation and functionality [25, 26]. We have 
shown in earlier work that the induction of Tregs depends on the H. pylori virulence factor and 
immunomodulator VacA; VacA mutants fail to induce suppressive Tregs and to confer asthma 
protection, and VacA alone, administered in purified form, recapitulates many of the beneficial 
effects of live infection [22, 30]. H. pylori VacA mutants fail to colonize persistently and at wild type 
levels, and rather are cleared effectively by an overshooting T-helper-1 response. The 
immunomodulatory effects of VacA were confirmed in the food allergy models presented here, and 
were reflected in the epigenetic signature of Tregs isolated from VacA-treated mice. The rationale 
for applying preventive treatments in contrast to therapeutic treatments (which would start after 
sensitization) with VacA was governed by our prior experience in asthma models, in which we 
reported preventive but not therapeutic efficacy of H. pylori-specific tolerization. In conclusion, H. 
pylori possesses strong immunomodulatory properties, mediated at least in part by the VacA 
protein, that allow it to modulate T-cell responses directed at the infection itself, as well as at 
conspicuous food and environmental antigens. These properties are evident not only locally in the 
gastric mucosa, but systemically, and strongly affect the individual carrier’s allergy risk.  
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Figure legends 
 
Figure 1. OVA- induced food allergy is ameliorated by neonatal H. pylori infection or weekly 
extract treatment. (A) Schematic of OVA-induced food allergy and H. pylori-specific interventions. 
Mice were sensitized twice intraperitoneally (i.p.) with 50 g of alum-adjuvanted OVA and orally 
challenged four weeks after the first sensitization on four consecutive days with 60 mg OVA (s/c; 
positive controls). Negative control animals were challenged but not sensitized, or neither sensitized 
nor challenged. One group of mice was neonatally infected on day 6 and 7 after birth with the H. 
pylori strain PMSS1 (inf), and another group was treated weekly by oral gavage with 100-200 g 
(adjusted to body weight) whole cell H. pylori extract starting on day 6 or 7 after birth (extr p.o.). (B) 
Cumulative anaphylaxis score assigned upon challenge (sum of three scores). s/c, sensitization and 
challenge. (C) Representative pictures showing mice with a score of 1 (repetitive scratching around 
nose and head, and hind-leg-ear-digging) and a score of 2 (puffing around eyes, pilar erecti, 
decreased activity). (D) Serum OVA-specific IgG1, as determined by ELISA. (E,F) Cytokine production, 
as determined by IL-5 and IL-13 ELISA, of splenocytes that had been re-stimulated in vitro with OVA 
for four days. In B,D,E and F, each symbol represents one mouse. Graphs show pooled data from 5 
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(B), 4 (D) and 2 (E,F) experiments. Horizontal lines indicate medians; the Kruskal-Wallis test followed 
by Dunn's multiple comparisons test was used throughout for the calculation of p-values.  
 
Figure 2. Amelioration of allergic symptoms in an oral challenge peanut allergy model upon H. 
pylori specific treatments. (A) Schematic of PE-induced food allergy and H. pylori interventions. Mice 
were sensitized four times by oral gavage (p.o.) with 2 mg of peanut-extract (PE) adjuvanted with 20 
g cholera toxin (CT), followed four weeks later by oral challenges on four consecutive days with 60 
mg OVA (positive controls). Negative control animals were challenged but not sensitized, or neither 
sensitized nor challenged. One group of mice was neonatally infected on day 6 and 7 after birth with 
the H. pylori strain PMSS1 (inf), and another group was treated weekly by oral gavage with 100-200 
g (adjusted to body weight) whole cell H. pylori extract starting on day 6 or 7 after birth (extr p.o.). 
A final group received once-weekly increasing doses (adjusted to body weight) of 5-20 g purified 
VacA (VacA i.p.) starting on day 6 or 7 after birth. (B) Cumulative anaphylaxis score assigned upon 
challenge (sum of three scores). (C,D) Serum PE-specific IgE and MCPT1 levels, as determined by 
ELISA. In B-D, each symbol represents one mouse. Graphs show pooled data from 4 (B), 3 (C) and 2 
(D) experiments. Horizontal lines indicate medians; the Kruskal-Wallis test followed by Dunn's 
multiple comparisons test was used throughout for the calculation of p-values.  
 
Figure 3. Systemically induced peanut food allergy is reduced upon neonatal H. pylori infection or 
weekly treatment with extract or VacA. (A) Schematic of PE-induced food allergy and H. pylori 
interventions. Mice were sensitized four times by oral gavage (p.o.) with 2 mg of peanut-extract (PE) 
adjuvanted with 20 g cholera toxin (CT), followed one week later by two i.p. challenges (with a 
three day interval) with 1 mg PE (positive controls). Negative control animals were challenged but 
not sensitized, or neither sensitized nor challenged. One group of mice was neonatally infected on 
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day 6 and 7 after birth with the H. pylori strain PMSS1 (inf), and another group was treated weekly 
by oral gavage or i.p. with whole cell H. pylori extract starting on day 6 or 7 after birth (extr p.o./i.p.). 
A final group received weekly increasing doses (adjusted to body weight) of 5-20 g purified VacA 
(VacA i.p.) starting on day 6 or 7 after birth. (B) Anaphylaxis score assigned at first challenge. (C) 
Representative pictures showing mice with a score of 3 (lying prone on stomach for more than one 
minute). (D,E) Cytokine production, as determined by IL-5 and IL-13 ELISA, of splenocytes that had 
been re-stimulated in vitro with PE for four days. In B,D, and E, each symbol represents one mouse. 
Graphs show pooled data from 8 (B) and 6 (D,E)  experiments. Horizontal lines indicate medians; the 
Kruskal-Wallis test followed by Dunn's multiple comparisons test was used throughout for the 
calculation of p-values.   
 
Figure 4. Decreased methylation of the Treg-specific-demethylated-region (TSDR) and increase in 
regulatory cytokine expression upon H. pylori-specific treatment. (A) Schematic overview of the 
FOXP3 locus with the TSDR upstream of the TSS (retrieved using BLAST). The CG-containing region is 
marked in blue and CG motifs covered by pyrosequencing are marked in bold red. (B) Methylation 
pattern of 10 CG dinucleotides within the TSDR, of FACS-sorted MLN-derived CD4+Foxp3+ and 
CD4+FoxP3- T-cells. Animals were treated as indicated. The methylation status of the individual CGs is 
color-coded (left panel). White cells indicate sequences that failed to yield interpretable results due 
to technical problems. (C) Frequencies of FoxP3+ Tregs among all TCR+ CD4+ T-cells, and of CD4+ and 
CD8+ T-cells among all CD45+ leukocytes in the MLNs of mice treated from 7 days of age onwards 
with either VacA, or H. pylori extract, or live bacteria. Horizontal lines represent medians. (D) 
Expression of FoxP3, IL-10 and TGF- by sorted CD4+CD25+ Tregs, as assessed by qRT-PCR and 
normalized to Hprt, of the mice shown in C. Means +SEM are shown. 
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